Fig. 5: Elane inhibits the degradation of Keap1. | Cell Death & Disease

Fig. 5: Elane inhibits the degradation of Keap1.

From: ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease

Fig. 5

A qRT‒PCR was used to assess Keap1 mRNA expression in primary hepatocytes after FFA and/or Elane treatment (n = 3). B qRT‒PCR was used to assess the mRNA half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). C, D Western blotting was used to assess the protein half-life of Keap1 after FFA and/or Elane treatment of primary hepatocytes (n = 3). E qRT‒PCR was used to assess the mRNA expression of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/− mice (n = 3). F qRT‒PCR was used to assess the mRNA half-life of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/− mice (n = 3). G, H Western blotting was used to assess the protein half-life of Keap1 in primary hepatocytes after modelling in Elane+/+ and Elane−/− mice (n = 3). I, J After MG132 (10 μM) was added for 4 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). K, L After the addition of CQ (20 μM) for 8 h, Western blotting was performed to assess the protein expression of Keap1 after FFA and/or Elane treatment, after which grayscale analysis was performed (n = 3). The data are presented as the means ± SDs. *P < 0.05, **P < 0.01, in comparison to the control group; ns not significant.

Back to article page